Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?
22
Citation
42
Reference
10
Related Paper
Citation Trend
Abstract:
Direct acting antivirals stabilize or improve liver function in the majority of patients with hepatitis C virus cirrhosis. Hepatic decompensation is the main driver of death of patients with early, successfully treated hepatocellular carcinoma superimposed to cirrhosis. Treatment with direct acting antivirals could improve the prognosis of these subjects, independently from the subsequent course of hepatocellular carcinoma, if the efficacy in obtaining viral clearance is as high as in patients without a history of hepatocellular carcinoma, and if the risk of hepatocellular carcinoma recurrence is unaffected. When dealing with hepatocellular carcinoma patients, direct acting antivirals can be indicated in two different settings: (a) subjects in which hepatocellular carcinoma has been already successfully treated ("cured" hepatocellular carcinoma), or (b) subjects whose hepatocellular carcinoma is still untreated or untreatable ("active" hepatocellular carcinoma). Although there are abundant data on "cured" hepatocellular carcinoma, evidence supporting treatment decisions in patients with "active" hepatocellular carcinoma is at best scarce and controversial, since these patients as well as patients with hepatocellular carcinoma listed for liver transplantation are usually excluded from treatment.Keywords:
Hepatitis virus
Liver Cancer
Hepatocellular cancer
Abstract We investigated whether the presence of hepatitis C virus (HCV) infection can be detected in hemostatic gauze used during oral treatments. We were able to detect both antibody to HCV and HCV RNA in samples from patients serologically proven to have HCV and also in gauze used for these patients that was left at room temperature even for as long as 24 hours. Thus, this method is useful for the screening of HCV infection in situations in which blood sampling is not feasible.
Hepatitis virus
Hepatitis C
Cite
Citations (3)
Objective To investigate the clinical efficacy of liver cancer resection combined with splenectomy in treatment of the hepatocellular cancer patients with hypersplenism.Method The data of liver function,changes of platelet count and white blood cell count in 12 hepatocellular cancer patients with hypersplenism were analyzed retrospectively.Results Three days after operation,the white blood cell count increased from(3.2 ± 1.7) × 109 /L to(13.5 ± 5.3) × 109 /L,the platelet count increased from(52.6 ± 23.7) × 109 /L to(245.3 ± 94.6) × 109 /L(P 0.01).The major parameters of the liver function recovered to their preoperational values within 1 week.Conclusion Liver cancer resection combined with splenectomy was effective for treatment of the hepatocellular cancer patients with hypersplenism.
Liver Cancer
Hepatocellular cancer
White blood cell
Liver function
Cite
Citations (0)
Liver Cancer
Hepatitis virus
Cite
Citations (0)
Liver Cancer
Hepatocellular cancer
Cancer Treatment
Cite
Citations (1,121)
OBJECTIVE:To analyze the incidence trend of liver cancer of Ninghe from 1988-2006 with the statistic method so as to offer the reference for liver cancer control progran.METHODS:The data of the incidence of liver cancer from 1988 to 2006 of Ninghe were collected,and according to the population structure of the 2000 national population census,the number of people of age-groups was reckoned and to calculate standardized morbidity rate(SMR).RESULTS:The SMR of liver cancer from 1988 to 2006 of County Ninghe was 21.04/100 000;liver cancer accounted for 15.01% of the whole malignant tumors,ranking the second place;the age-specific incidence rate went up year after year,and the peak of the liver cancer incidence the 60 ～70 years old,and the ratio of men to women was 2.49;the incidence of hepatocellular cancer was gradually increasing year by year.CONCLUSION:The liver cancer incidence of Ninghe is high,and there is a rising trend.The old is the main population of liver cancer.
Liver Cancer
Hepatocellular cancer
Cancer Incidence
Standardized mortality ratio
Cite
Citations (0)
The association of hepatitis C virus (HCV) with neoplasia is not completely understood. Hepatitis C virus is hepatolymphotrophic. It is considered an inducing factor of hepatocellular carcinoma (HCC) and is associated with various types of lymphomas. We describe a patient with HCV cirrhosis who developed gastric lymphoma and HCC, and we review the current data and theories about the oncogenesis of HCV.
Hepatitis virus
Hepatitis C
Cite
Citations (13)
Liver Cancer
Hepatitis virus
Etiology
Cite
Citations (2)
The review presents epidemiological data on the prevalence of hepatocellular liver cancer (HCC) in different countries of the world including the Republic of Belarus, that belongs to the countries with a low prevalence of HCC. The review also contains information about variants of liver cancer associated with various hepatotropic viruses (HBV, HCV, HDV), the pathological process in which manifests itself as a mono or mixed viral infection. The mechanisms of transformation of an infectious process into an oncological one are considered. The importance of liver cirrhosis fibrosis in the development of cancer as a competing disease, the peculiarities of the morphological picture in the liver and the effect of therapy on the course of cirrhosis and hepatocellular liver cancer are emphasized.
Liver Cancer
Hepatocellular cancer
Viral Hepatitis
Liver disease
Cite
Citations (7)
Objective:To observe effect and safety of Aiyishu injection combined with TACE(trans-arterial chemoembolization)in liver cancer.Methods:100 liver cancer patients were divided into Aiyishu group and control group randomly.Both of them received THP plus iodine oil TACE.Aiyishu group received Aiyishu 50 ml iv daily continued 4 weeks.Objective effect,QOL(quality of life),symptom improve rate and side-effect were evaluated after 4 weeks.Results:There were no obvious difference between two groups in objective effect and side-effect.But QOL in Aiyishu group was higher than control group(P0.05).The symptom improve rate in Aiyishu group and control group was 74.51% and 57.14%.Conclusion:Aiyishu injection increase the QOL and symptom improve rate in liver cancer patients after TACE.
Liver Cancer
Hepatocellular cancer
Transcatheter arterial chemoembolization
Therapeutic effect
Life quality
Cite
Citations (1)
Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare (< 1%) primary liver cancer which contains elements of hepatocellular cancer (HCC) and bile duct cancer (CC). On account of the difficulties in reaching preoperative diagnosis, it is frequently diagnosed only after resection is performed. A surgical resection of the liver is the treatment of choice, whilst a liver transplant is a rarely implemented option. The prognosis of cHCC-CC tumours is better than in CC but worse than in HCC. This paper presents the case report of a 62-year-old man undergoing a left hemihepatectomy for a cHCC-CC liver tumour.
Hepatocellular cancer
Liver Cancer
Bile duct cancer
Cite
Citations (0)